BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 23063577)

  • 1. Fatal liver failure in a patient treated with sunitinib for renal cell carcinoma.
    Mermershtain W; Lazarev I; Shani-Shrem N; Ariad S
    Clin Genitourin Cancer; 2013 Mar; 11(1):70-2. PubMed ID: 23063577
    [No Abstract]   [Full Text] [Related]  

  • 2. Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate.
    Nicholaou T; Wong R; Davis ID
    Lancet; 2007 Jun; 369(9577):1923-4. PubMed ID: 17560435
    [No Abstract]   [Full Text] [Related]  

  • 3. Sunitinib as adjuvant therapy for renal cell carcinoma.
    Baker H
    Lancet Oncol; 2016 Nov; 17(11):e485. PubMed ID: 27773485
    [No Abstract]   [Full Text] [Related]  

  • 4. Pazopanib outscores sunitinib on tolerability.
    Cancer Discov; 2014 Jan; 4(1):OF8. PubMed ID: 24402960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Tumor lysis syndrome in a patient with a renal carcinoma treated with sunitinib].
    Rodríguez-Reimúndes E; Perazzo F; Vilches AR
    Medicina (B Aires); 2011; 71(2):158-60. PubMed ID: 21550933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment with sunitinib and hypothyroidism--a case report and overview of literature].
    Kreze A; Stáhalová V; Zadrazilová A; Koskuba J; Kosák M
    Klin Onkol; 2009; 22(4):176-8. PubMed ID: 19731880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefits of pazopanib over sunitinib for renal cell carcinoma.
    Granovetter M
    Lancet Oncol; 2016 Mar; 17(3):e93. PubMed ID: 26853821
    [No Abstract]   [Full Text] [Related]  

  • 8. Sunitinib-induced microangiopathic hemolytic anemia with fatal outcome.
    Talebi TN; Stefanovic A; Merchan J; Lian E; Silva O
    Am J Ther; 2012 Jul; 19(4):e143-5. PubMed ID: 21403468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sunitinib-induced thyrotoxicosis - a not so rare entity.
    Jazvić M; Prpić M; Jukić T; Murgić J; Jakšić B; Kust D; Prgomet A; Bolanča A; Kusić Z
    Anticancer Res; 2015 Jan; 35(1):481-5. PubMed ID: 25550591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of antiangiogenic therapy-induced hypertension.
    de Jesus-Gonzalez N; Robinson E; Moslehi J; Humphreys BD
    Hypertension; 2012 Sep; 60(3):607-15. PubMed ID: 22851729
    [No Abstract]   [Full Text] [Related]  

  • 11. Sunitinib and hypothyroidism.
    Wolter P; Dumez H; Schöffski P
    N Engl J Med; 2007 Apr; 356(15):1580; author reply 1580-1. PubMed ID: 17429091
    [No Abstract]   [Full Text] [Related]  

  • 12. Fatigue with sunitinib-induced hypothyroidism.
    Senior K
    Lancet Oncol; 2007 Feb; 8(2):101. PubMed ID: 17288042
    [No Abstract]   [Full Text] [Related]  

  • 13. Lethal acute liver failure in a patient treated with sunitinib.
    Guillen SS; Meijer M; de Jongh FE
    BMJ Case Rep; 2016 Mar; 2016():. PubMed ID: 26933184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe rhabdomyolysis during sunitinib treatment of metastatic renal cell carcinoma. A report of two cases.
    Ruggeri EM; Cecere FL; Moscetti L; Doni L; Padalino D; Di Costanzo F
    Ann Oncol; 2010 Sep; 21(9):1926-1927. PubMed ID: 20729535
    [No Abstract]   [Full Text] [Related]  

  • 15. Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma.
    Michels J; Lassau N; Gross-Goupil M; Massard C; Mejean A; Escudier B
    Invest New Drugs; 2010 Oct; 28(5):690-3. PubMed ID: 19547920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression of a caval vein thrombus in two patients with primary renal cell carcinoma on pretreatment with sunitinib.
    Bex A; Van der Veldt AA; Blank C; Meijerink MR; Boven E; Haanen JB
    Acta Oncol; 2010 May; 49(4):520-3. PubMed ID: 20105087
    [No Abstract]   [Full Text] [Related]  

  • 17. The use of sunitinib in renal cell carcinoma: where are we now?
    Czarnecka AM; Szczylik C; Rini B
    Expert Rev Anticancer Ther; 2014 Sep; 14(9):983-99. PubMed ID: 25066545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lower limbs erosions induced by sunitinib.
    Kluger N; Chapelle A; Jacot W; Guillot B
    Acta Derm Venereol; 2011 May; 91(3):360-1. PubMed ID: 21103845
    [No Abstract]   [Full Text] [Related]  

  • 19. [Role of VEGFR-TKIs in the treatment of renal cell carcinoma].
    Kondo T
    Nihon Jinzo Gakkai Shi; 2012; 54(5):574-80. PubMed ID: 22991835
    [No Abstract]   [Full Text] [Related]  

  • 20. Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice.
    Schmidinger M; Arnold D; Szczylik C; Wagstaff J; Ravaud A
    Cancer Invest; 2010 Oct; 28(8):856-64. PubMed ID: 20504222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.